NCT05128058View on ClinicalTrials.gov

A Target Occupancy Study With Ritlecitinib.

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

October 22, 2021

Primary Completion Date

January 14, 2022

Study Completion Date

January 14, 2022

Conditions

Healthy

Interventions

DRUG

Ritlecitinib 50 mg

50 mg single dose

DRUG

Ritlecitinib 200 mg

200 mg single dose

Trial Locations (1)

06511

Pfizer Clinical Research Unit - New Haven, New Haven

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY

NCT05128058 - A Target Occupancy Study With Ritlecitinib. | Biotech Hunter | Biotech Hunter